Found: 7
Select item for more details and to access through your institution.
Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52‐week analysis of a postmarketing surveillance study in Japan.
- Published in:
- Journal of Dermatology, 2023, v. 50, n. 8, p. 1034, doi. 10.1111/1346-8138.16835
- By:
- Publication type:
- Article
Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan.
- Published in:
- Journal of Dermatology, 2022, v. 49, n. 4, p. 411, doi. 10.1111/1346-8138.16297
- By:
- Publication type:
- Article
Smallpox and Season: Reanalysis of Historical Data.
- Published in:
- Interdisciplinary Perspectives on Infectious Diseases, 2009, p. 1, doi. 10.1155/2009/591935
- By:
- Publication type:
- Article
Real-world effectiveness and safety of adalimumab for treatment of ankylosing spondylitis in Japan.
- Published in:
- Modern Rheumatology, 2019, v. 29, n. 6, p. 1007, doi. 10.1080/14397595.2018.1525024
- By:
- Publication type:
- Article
Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correction to: Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.
- Published in:
- Pediatric Drugs, 2018, v. 20, n. 1, p. 97, doi. 10.1007/s40272-017-0264-y
- By:
- Publication type:
- Article